Differences in growth factor (GF) signaling may cause the poor prognosis in some breast cancer cases. A new study suggests that some estrogen receptor-positive breast cancers respond poorly to tamoxifen because of increased GF signaling.
Differences in growth factor (GF) signaling may cause the poor prognosis in some breast cancer cases. A new study suggests that some estrogen receptor-positive breast cancers respond poorly to tamoxifen because of increased GF signaling.